The addition of the HER2-directed antibody trastuzumab to chemotherapy also increased the overall survival rate of patients with metastatic HER2-positive esophago-gastric cancer, although targeting HER2 still remains challenging due to the complex biology of this receptor in gastric and esophageal cancers. This evidence concerns the gene ERBB2 and gastric cancer.